Cash, cash equivalents and investments totaled USD 117.9 million at June 30, 2026, expected to fund operations into 2028.
Q2 FY26 financial results
Corbus posted a net loss of USD 35.04 million in Q2 2026, widening from USD 17.66 million a year earlier; loss per share widened to USD 1.81.
Total operating expenses rose 88.96% to USD 36.19 million, driven by higher clinical development costs including a USD 10 million CRB-701 milestone payment.
Pipeline and clinical program updates
The FDA cleared the TEMPO-1 registrational study of CRB-701 in second-line oropharyngeal cancer; enrollment is expected to start in September 2026.
The CANYON-1 Phase 1b obesity trial of CRB-913 reached last patient last visit; topline data are slated for .
CRBP•
